Your session is about to expire
← Back to Search
18F-FSPG PET/CT Imaging for Lung Cancer
Study Summary
This trial is testing a new imaging agent, 18F-FSPG, to see if it can help diagnose early lung cancer in patients with lung nodules.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 46 Patients • NCT02448225Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have smoked at least 20 pack-years.I have been diagnosed with lung cancer before.I was diagnosed with cancer within the last 5 years.I have a lung nodule between 7 to 30 mm, or multiple with one dominant in this size range.I am scheduled for a PET scan to check a lung nodule.
- Group 1: Diagnostic (18F-FSPG PET/CT, 18F-FDG PET/CT)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are patients currently being recruited for this trial?
"That is correct, the information on clinicaltrials.gov does say that this study is looking for volunteers at the moment. The posting date was February 4th, 2019 and the most recent update was June 16th, 2022. They are searching for 50 individuals total from one location."
Does BAY94-9392 have FDA approval for treating patients with Fluorine F 18 L-glutamate?
"This chemical, Fluorine F 18 L-glutamate Derivative BAY94-9392, is currently in Phase 2 of clinical trials. This means that while there is evidence suggesting it is safe, none yet affirms that it is an effective medication."
What medical conditions does Fluorine F 18 L-glutamate Derivative BAY94-9392 help alleviate?
"Fluorine F 18 L-glutamate Derivative BAY94-9392 is often used to ameliorate the effects of CAD. This medication can also improve outcomes for patients with malignancies, positron emission tomography, and left ventricular dysfunction."
How many individuals are being treated as part of this clinical research?
"That is correct. According to the information found on clinicaltrials.gov, this study was originally posted on February 4th, 2019 and is actively recruiting patients at this time. The goal is to enroll 50 individuals from 1 location."
What other scientific studies have been done using Fluorine F 18 L-glutamate Derivative BAY94-9392?
"Right now, there are 26 ongoing studies investigating Fluorine F 18 L-glutamate Derivative BAY94-9392. Out of these, 2 are large Phase 3 clinical trials. Most research surrounding this topic is based in New york City; however, one can find 56 different trial locations across the United States."
Share this study with friends
Copy Link
Messenger